Felip et al. [12] found that ABTL0812 (an anti-cancer drug) inhibited the PI3K/AKT/mTORC1 axis by up-regulating the expression of TRIB3 to sensitize endometrial cancer cells. This evidence concerns the gene TRIB3 and endometrial cancer.